REZOLUTE, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
REZOLUTE, INC. (RZLT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $2.50 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-24.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-09-24
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $200.00K, a 50.00% decline year-over-year.
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $500.00K.
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $200.00K, a 50.00% decline year-over-year.
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $1.60M, a 1500.00% increase year-over-year.
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2026 was $2.50M, a 177.78% increase from fiscal 2025.
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $900.00K, a 800.00% increase from fiscal 2024.
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $100.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-24 | $700.00K derived: sum of 2 quarters · filed 2026-09-24 | $900.00K derived: sum of 3 quarters · filed 2026-09-24 | $2.50M 10-K · filed 2026-09-24 |
| 2026-03-31 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-12 | $700.00K derived: sum of 2 quarters · filed 2026-05-12 | $2.30M 10-Q · filed 2026-05-12 | $2.70M derived: sum of 4 quarters · filed 2026-09-24 |
| 2025-12-31 | $200.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-12 | $1.80M 10-Q · filed 2026-02-12 | $2.20M derived: sum of 3 quarters · filed 2026-09-24 | $2.20M derived: sum of 4 quarters · filed 2026-09-24 |
| 2025-09-30 | $1.60M 10-Q · filed 2025-11-06 | $2.00M derived: sum of 2 quarters · filed 2026-09-24 | $2.00M derived: sum of 3 quarters · filed 2026-09-24 | $2.40M derived: sum of 4 quarters · filed 2026-09-24 |
| 2025-06-30 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-24 | $400.00K derived: sum of 2 quarters · filed 2026-09-24 | $800.00K derived: sum of 3 quarters · filed 2026-09-24 | $900.00K 10-K · filed 2026-09-24 |
| 2025-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-13 | $400.00K derived: sum of 2 quarters · filed 2025-05-13 | $500.00K 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-12 | $500.00K 10-Q · filed 2025-02-12 | ||
| 2024-09-30 | $100.00K 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $100.00K 10-K · filed 2025-09-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |